Metformin for COVID-19: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed

5 hours ago

Metformin for COVID-19 did not show significant reduction in a composite outcome of hospitalization, emergency department visits, or death according to a meta-analysis of four randomized controlled trials.
No significant differences were observed between metformin and placebo groups regarding all-cause mortality and serious adverse events.
The analysis suggests metformin may offer modest benefits, but results are based on limited trials and low event rates, requiring caution in interpretation.

Hasty Briefsbeta